This trial is evaluating whether Palliative radiotherapy will improve 1 primary outcome in patients with Neoplasm Metastasis. Measurement will happen over the course of 6 month.
This trial requires 58 total participants across 1 different treatment group
This trial involves a single treatment. Palliative Radiotherapy is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"Neoplasms are the second leading source of deaths in children after accidents, injuries, and burns. In the future, we will need to develop a better understanding of cancer genetics so that appropriate preventive measures can be implemented." - Anonymous Online Contributor
"Palliative radiotherapy has been widely used in the management of a variety of tumors and conditions. While many patients believe that radiotherapy reduces pain and improves quality of life, this does not seem to be supported by the evidence. Patients should ask their physicians how much radiotherapy they will receive to help them make an informed decision about therapy." - Anonymous Online Contributor
"In a recent study, we found that the majority of patients treated (88%) received palliative RT for local control. The usual area(s) of involvement were bones and spine. Radiation therapy was also frequently used for pain relief, especially in patients with neurologic symptoms. The main reasons for non-use of RT were lack of response to the initial treatment regimen and patient preference." - Anonymous Online Contributor
"Data from a recent study of this study suggest that the time from surgery to metastasis is not related to tumor size. Furthermore, metastasis may occur at any time during the follow-up period, regardless of tumor size. Therefore, the determination of metastatic dissemination seems to be a random event in this disease." - Anonymous Online Contributor
"Recent findings showed that palliative RT was associated with better QOL than no RT. Future well-designed randomized controlled trials should include assessments of QOL to provide evidence for the benefit of palliative RT." - Anonymous Online Contributor
"Palliative RT improves pain and QOL compared with other treatments; however, it has no impact on OS. In particular, as the disease progresses, locoregional control is significantly improved whereas distant metastasis is unaffected." - Anonymous Online Contributor
"RT is an effective and well tolerated treatment for patients with unresectable distant cancer, especially when administered during the palliative period. Recent findings suggest that RT should be considered as one of the possible therapeutic options in advanced cancer patients." - Anonymous Online Contributor
"In specific cases it is possible to achieve complete remission of metastatic lesions after surgical treatment. On the basis of our short follow up this approach can be recommended only on the basis of a clinical assessment." - Anonymous Online Contributor
"Radiotherapy has been an effective treatment for many malignant tumors and has contributed to the survival of hundreds of thousands of people worldwide. Although palliative radiotherapy is no longer used routinely for treating solid tumors, it remains an important tool in the management of advanced cancer." - Anonymous Online Contributor
"Although neoplasm metastasis is uncommon, it still occurs and can be fatal. For example, in the U.S., [12,000 people per year die from metastatic [colorectal cancer](https://www.withpower.com/clinical-trials/colorectal-cancer)] because of poor prognosis and insufficient treatment.[current cancer treatment]." - Anonymous Online Contributor
"Clinical trials on cancer patients seem to be worthwhile, even if they do not show any significant effect on survival. Patients with metastatic disease are more likely to benefit from clinical trials. However, this risk must be balanced against the risks of toxicity and costs. Careful patient selection and adequate consent procedures are mandatory before starting any cancer drug studies." - Anonymous Online Contributor